R-6600 Ruxolitinib, Free Base, >99%

Synonyms : [INCB018424] [INCB18424] [NCB018424] [NCB18424]

Related Terms : [Jakafi]

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 41
  • 36
  • 32
  • 4,400
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 54
  • 48
  • 43
  • 5,800
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 79
  • 70
  • 63
  • 8,500
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 99
  • 88
  • 79
  • 10,700
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 145
  • 129
  • 116
  • 15,600
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 218
  • 194
  • 174
  • 23,500
  • Add to Cart Qty:
  • In stock
  • 250 mg
  • 247
  • 219
  • 197
  • 26,600
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 425
  • 378
  • 340
  • 45,800
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 732
  • 651
  • 585
  • 78,900
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 1,220
  • 1,085
  • 976
  • 131,400
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 306.37
  • C17H18N6
  • [941678-49-5]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 28 mg/mL; soluble in ethanol at 15 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 25-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • More than 70 labs worldwide have purchased Ruxolitinib or its salt forms from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
  • This is the free base form of ruxolitinib, also known as INCB18424; please see the other form of this product, Ruxolitinib, Phosphate Salt, Cat. No. R-6688, for further technical information. The phosphate salt form of ruxolitinib is used for some or all ruxolitinib formulations for use in humans.
  • Ruxolitinib (as the phosphate salt) is the active ingredient in the drug sold under the trade name Jakafi® by Incyte Corporation. Jakafi® is currently approved in at least one country for use in patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. NOTE: THE RUXOLITINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT JAKAFI® AND IS NOT FOR HUMAN USE. Jakafi® is a registered trademark of Incyte Corporation. LC Laboratories is not affiliated with Incyte Corporation, and the ruxolitinib research compounds sold by LC Laboratories are not manufactured by Incyte Corporation.
  • This ruxolitinib product research compound is the free base, whose CAS number is given above. The CAS number of the phosphate salt is 1092939-17-7.
  • As of September 2011, it appears that Chemical Abstracts Service currently also has a second CAS number for Ruxolitinib, Free Base, namely 1160597-27-2.
  • Another CAS number previously assigned to Ruxolitinib, Free Base, namely 1138325-12-8, has been deleted by CAS and is no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
269